|
Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide
|
Apr 2020
|
Blood Advances
|
aplastic anemia
|
|
Rewriting the rules for care of MDS and AML patients in the time of COVID-19
|
Apr 2020
|
Leukemia Research Reports
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Alcohol use is not a significant contributor to myelodysplastic syndromes
|
Apr 2020
|
Cancer Causes & Control : CCC
|
myelodysplastic syndromes (MDS)
|
|
Targeting TP53 Mutations in Myelodysplastic Syndromes
|
Apr 2020
|
Hematology/oncology clinics of North America
|
myelodysplastic syndromes (MDS)
|
|
Evolving therapies for lower-risk myelodysplastic syndromes
|
Apr 2020
|
Annals of Hematology
|
myelodysplastic syndromes (MDS)
|
|
Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities
|
Mar 2020
|
Clinical Lymphoma , Myeloma & Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
|
Mar 2020
|
Expert Review of Hematology
|
myelodysplastic syndromes (MDS)
|
|
Clonal selection in therapy related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment
|
Jan 2020
|
European Journal of Haematology
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria
|
Jan 2020
|
Haematologica
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
|
Jan 2020
|
The New England Journal of Medicine
|
myelodysplastic syndromes (MDS)
|
